DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 144 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,147 | -64.4% | 1,348 | -60.6% | 0.00% | – |
Q2 2023 | $48,210 | -27.7% | 3,424 | -20.7% | 0.00% | – |
Q1 2023 | $66,713 | -8.9% | 4,318 | -3.4% | 0.00% | – |
Q4 2022 | $73,247 | -18.6% | 4,469 | -7.7% | 0.00% | – |
Q3 2022 | $90,000 | +69.8% | 4,840 | +19.4% | 0.00% | – |
Q2 2022 | $53,000 | +194.4% | 4,052 | +100.6% | 0.00% | – |
Q1 2022 | $18,000 | -21.7% | 2,020 | -14.0% | 0.00% | – |
Q4 2021 | $23,000 | -66.2% | 2,348 | +18.5% | 0.00% | – |
Q3 2021 | $68,000 | +15.3% | 1,981 | +22.7% | 0.00% | – |
Q2 2021 | $59,000 | -89.4% | 1,615 | -87.0% | 0.00% | -100.0% |
Q1 2021 | $559,000 | -21.9% | 12,467 | -0.6% | 0.00% | -50.0% |
Q4 2020 | $716,000 | +26.1% | 12,543 | +13.3% | 0.00% | +100.0% |
Q3 2020 | $568,000 | +222.7% | 11,073 | +275.1% | 0.00% | – |
Q2 2020 | $176,000 | +112.0% | 2,952 | +46.6% | 0.00% | – |
Q1 2020 | $83,000 | +3.8% | 2,013 | +56.9% | 0.00% | – |
Q4 2019 | $80,000 | +247.8% | 1,283 | +91.8% | 0.00% | – |
Q3 2019 | $23,000 | – | 669 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
New Leaf Venture Partners, L.L.C. | 1,209,571 | $69,030,000 | 15.95% |
SV Health Investors, LLC | 449,951 | $25,679,000 | 12.37% |
Sunesis Advisors, LLC | 96,299 | $5,496,000 | 4.45% |
Redmile Group, LLC | 4,437,968 | $253,275,000 | 3.07% |
Consonance Capital Management LP | 484,671 | $27,660,000 | 2.58% |
SECTORAL ASSET MANAGEMENT INC | 488,842 | $27,898,000 | 1.97% |
Opaleye Management Inc. | 222,000 | $12,670,000 | 1.66% |
Eversept Partners, LP | 246,240 | $14,052,917 | 1.65% |
SILVERARC CAPITAL MANAGEMENT, LLC | 38,620 | $2,204,000 | 1.28% |
Avoro Capital Advisors LLC | 1,300,000 | $74,191,000 | 1.28% |